Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.

Prather PL, FrancisDevaraj F, Dates CR, Greer AK, Bratton SM, Ford BM, Franks LN, Radominska-Pandya A.

Biochem Biophys Res Commun. 2013 Nov 15;441(2):339-43. doi: 10.1016/j.bbrc.2013.10.057. Epub 2013 Oct 19.

2.

Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.

Ford BM, Franks LN, Radominska-Pandya A, Prather PL.

PLoS One. 2016 Dec 9;11(12):e0167240. doi: 10.1371/journal.pone.0167240. eCollection 2016.

3.

Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity.

Franks LN, Ford BM, Prather PL.

Front Pharmacol. 2016 Dec 22;7:503. doi: 10.3389/fphar.2016.00503. eCollection 2016.

4.

Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.

Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S, Selley DE.

Mol Pharmacol. 2006 Jul;70(1):41-50. Epub 2006 Mar 29.

5.

Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs.

Franks LN, Ford BM, Madadi NR, Penthala NR, Crooks PA, Prather PL.

Eur J Pharmacol. 2014 Aug 15;737:140-8. doi: 10.1016/j.ejphar.2014.05.007. Epub 2014 May 20.

6.

Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.

Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL.

Toxicol Appl Pharmacol. 2013 Jun 1;269(2):100-8. doi: 10.1016/j.taap.2013.03.012. Epub 2013 Mar 26.

7.

AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.

Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL.

Neuropharmacology. 2012 Oct;63(5):905-15. doi: 10.1016/j.neuropharm.2012.06.046. Epub 2012 Jul 4.

8.

The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.

Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL.

J Pharmacol Exp Ther. 2005 Aug;314(2):868-75. Epub 2005 May 18.

10.

Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.

Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.

Anticancer Res. 2006 May-Jun;26(3A):1773-84.

12.

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.

Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG.

Br J Pharmacol. 2007 Mar;150(5):613-23. Epub 2007 Jan 22.

13.

CB2 cannabinoid receptor is a novel target for third-generation selective estrogen receptor modulators bazedoxifene and lasofoxifene.

Kumar P, Song ZH.

Biochem Biophys Res Commun. 2014 Jan 3;443(1):144-9. doi: 10.1016/j.bbrc.2013.11.071. Epub 2013 Nov 23.

14.

Synthesis and biological evaluation of (3',5'-dichloro-2,6-dihydroxy-biphenyl-4-yl)-aryl/alkyl-methanone selective CB2 inverse agonist.

Presley CS, Mustafa SM, Abidi AH, Moore BM 2nd.

Bioorg Med Chem. 2015 Sep 1;23(17):5390-401. doi: 10.1016/j.bmc.2015.07.057. Epub 2015 Jul 29.

PMID:
26275680
15.

3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.

Wiley JL, Selley DE, Wang P, Kottani R, Gadthula S, Mahadeven A.

J Pharmacol Exp Ther. 2012 Feb;340(2):433-44. doi: 10.1124/jpet.111.187815. Epub 2011 Nov 15.

17.

Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway.

Dhopeshwarkar A, Mackie K.

J Pharmacol Exp Ther. 2016 Aug;358(2):342-51. doi: 10.1124/jpet.116.232561. Epub 2016 May 18.

18.

SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.

Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Pério A, Poncelet M, Maruani J, Arnone M, Finance O, Soubrié P, Le Fur G.

J Pharmacol Exp Ther. 2004 Sep;310(3):905-14. Epub 2004 May 6.

19.

Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.

Xu JJ, Diaz P, Astruc-Diaz F, Craig S, Munoz E, Naguib M.

Anesth Analg. 2010 Jul;111(1):99-109. doi: 10.1213/ANE.0b013e3181e0cdaf. Epub 2010 Jun 3.

20.

Supplemental Content

Support Center